Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MBRX - Moleculin Biotech Inc


IEX Last Trade
2.57
0.030   1.167%

Share volume: 9,312
Last Updated: Fri 30 Aug 2024 09:13:16 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$2.54
0.03
1.18%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
14%
Profitability 0%
Dept financing 9%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
Performance
5 Days
6.69%
1 Month
-19.30%
3 Months
-45.04%
6 Months
-72.13%
1 Year
-69.91%
2 Year
-88.44%
Key data
Stock price
$2.57
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.12 - $15.75
52 WEEK CHANGE
-$0.69
MARKET CAP 
6.532 M
YIELD 
N/A
SHARES OUTSTANDING 
2.562 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.35
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$22,741
AVERAGE 30 VOLUME 
$54,739
Company detail
CEO:
Region: US
Website: http://www.moleculin.com/
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.

Recent news